Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin

Mezghrani, Omar; Tang, Yue; Xue, Ke; Chen, Yi; Hu, Danrong; Tu, Jiasheng; Zhao, Li; Bourkaib, Nadia

doi:10.1016/j.ijpharm.2014.10.041

Cited by 71 publications

(46 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, GA-HA conjugate was developed by chemical reactions and loaded with chemotherapeutic agents. 262,263 All results indicate that GA-HA NPs seem to be a potential drug carrier with "double target sites" for HCC intracellular delivery. Due to degradation of HA by HAase, HA has been applicable to compose smart delivery system as HAase-responded shell and active ligand.…”

Section: Dual-ligand Modification To Further Enhance Active Targetingmentioning

confidence: 95%

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Li¹,

Zhang²,

Wang³

et al. 2016

IJN

112

View full text Add to dashboard Cite

Section: Dual-ligand Modification To Further Enhance Active Targetingmentioning

confidence: 95%

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Li¹,

Zhang²,

Wang³

et al. 2016

IJN

112

View full text Add to dashboard Cite

“…There are one possible reason that may account for the higher antitumor efficiency exhibited by Dex-SS-PAA-DOX NGs if comparing it with Dex-MBA-PAA-DOX. The acidic and reductive environment encountered at the tumor sites triggers the accelerated release of DOX45. This feature has contributed to improve the antitumor efficiency of the Dex-SS-PAA-DOX NGs.…”

Section: Resultsmentioning

confidence: 99%

“…Various concentrations of DOX solutions were used to calibrate the absorption of Dex-SS-PAA-DOX NCs at 480 nm. The drug loading content (LC) and drug encapsulation efficiency (EE) were calculated according to Formula 1 and 2:45…”

Section: Methodsmentioning

confidence: 99%

Self-Assembly Assisted Fabrication of Dextran-Based Nanohydrogels with Reduction-Cleavable Junctions for Applications as Efficient Drug Delivery Systems

Wang

Dai

Zhou

et al. 2017

Sci Rep

View full text Add to dashboard Cite

In order to overcome the key challenge in improving both fabrication efficiency and their drug delivery capability of anti-cancer drug delivery systems (ACDDS), here polyacrylic acid (PAA) grafted dextran (Dex) nanohydrogels (NGs) with covalent crosslinked structure bearing redox sensitive disulfide crosslinking junctions (Dex-SS-PAA) were synthesized efficiently through a one-step self-assembly assisted methodology (SAA). The Dex-SS-PAA were subsequently conjugated with doxorubicin through an acid-labile hydrazone bond (Dex-SS-PAA-DOX). The in vitro drug release behavior, anti-cancer effects in vivo, and biosafety of the as-prepared acid- and redox-dual responsive biodegradable NGs were systematically investigated. The results revealed that the Dex-SS-PAA-DOX exhibited pH- and redox-controlled drug release, greatly reduced the toxicity of free DOX, while exhibiting a strong ability to inhibit the growth of MDA-MB-231 tumors. Our study demonstrated that the Dex-SS-PAA-DOX NGs are very promising candidates as ACDDS for anti-cancer therapeutics.

show abstract

“…From these results, we calculated the CMC of the copolymer was 2.56×10 -3 mg/mL, which is fairly low compared to low molecular weight surfactants. 43 The fraction ratio of hydrophobic part and hydrophilic part of the copolymer was similar in the micelles, which contributed to the low CMC value. 44 Low CMC value ensured the preservation of micelle stability and structural integrity under high dilution conditions that could be encountered in vivo.…”

Section: Statistical Analysesmentioning

confidence: 99%

Preparation, characterization, in vivo pharmacokinetics, and biodistribution of polymeric micellar dimethoxycurcumin for tumor targeting

Liu¹,

Xu²,

Jiang³

et al. 2015

IJN

View full text Add to dashboard Cite

Dimethoxycurcumin (DMC) is an analog of curcumin with superior efficacy in various disease models. Currently, drug delivery system research on DMC is very limited, and it has become a huge challenge to realize further developments and clinical applications. In the present study, a kind of amphiphilic block copolymer, N- t -butoxycarbonyl-phenylalanine terminated monomethoxyl poly (ethylene glycol)-b-poly (ε-caprolactone), or mPEG-PCL-Phe(Boc), was prepared from monomethoxyl poly (ethylene glycol)-b-poly (ε-caprolactone) (mPEG-PCL) with its hydroxyl terminal chemically converted into N- t -butoxycarbonyl-phenylalanine (Boc-Phe). This copolymer was determined to have a fairly low critical micelle concentration (2.56×10 −3 mg/mL) and passive targeting potential to tumor tissue, and thus was applied to develop a polymeric micellar formulation of DMC for the first time. The DMC-loaded micelles prepared by thin-film hydration method had typical shell–core structure, with an average particle size of 17.9±0.4 nm and a polydispersity index of 0.045±0.011. The drug loading capacity and entrapment efficiency were 9.94%±0.15% and 97.22%±0.18%, respectively, indicating a high-affinity interaction between DMC and the copolymer. At a concentration of 2 mg/mL, the reconstituted micelle solution could be maintained for at least 10 days at room temperature, and displayed a low initial burst release followed by a sustained release in vitro. Pharmacokinetic study in rats revealed that in vivo drug exposure of DMC was significantly increased and prolonged by intravenously administering DMC-loaded micelles when compared with the same dose of free DMC dissolved in dimethyl sulfoxide. Furthermore, in vivo distribution results from tumor-bearing nude mice demonstrated that this micellar formulation significantly changed the biodistribution profile of DMC and increased drug accumulation in tumors. Therefore, the polymeric micellar formulation of DMC, based on the amphiphilic block copolymer, mPEG-PCL-Phe(Boc), could provide a desirable method for delivering DMC, especially for applications in cancer therapy.

show abstract

Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin

Cited by 71 publications

References 44 publications

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Self-Assembly Assisted Fabrication of Dextran-Based Nanohydrogels with Reduction-Cleavable Junctions for Applications as Efficient Drug Delivery Systems

Preparation, characterization, in vivo pharmacokinetics, and biodistribution of polymeric micellar dimethoxycurcumin for tumor targeting

Contact Info

Product

Resources

About